CELG
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FCELG.O%2Fkey-developments%2Farticle%2F2616750&ei=knKaUrDjLa210AHc1AE&usg=AFQjCNHj4JzLluSLk6Ck0bT9S29lohBuBQ
Celgene Corp's ABRAXANE Meets Primary Endpoint Of Progression-Free Survival In Phase III Chemotherapy-Naïve Metastatic Melanoma Study
Tuesday, 2 Oct 2012 07:30am EDT
Celgene Corp announced that Celgene International Sàrl, a subsidiary of Celgene Corporation announced results of phase III, randomized, international study (CA033) of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in chemotherapy-naïve patients with metastatic melanoma. In the study, the primary endpoint was met with patients receiving ABRAXANE demonstrating a statistically improvement in progression-free survival compared to patients receiving dacarbazine (DTIC) chemotherapy. 
